No Detail Found!

Frequency of HER-2positive and expression pattern in gastric adenocarcinoma by immunohistochemistry

Author(s)
Shahnawar Gulzar Department of Histopathology, Shifa International Hospitals,Islamabad,Pakistan
Nadira Mamoon Department of Histopathology, Shifa International Hospitals,Islamabad,Pakistan
Imran Nazir Department of Histopathology, Shifa International Hospitals,Islamabad,Pakistan
Zafar Ali Department of Histopathology, Shifa International Hospitals,Islamabad,Pakistan
Abstract
Objective: To determine the frequency and cardia, gastroesophageal junction and gastric expression of HER2/neu positivity by immuno- fundus was found to be 6 (14.3%), 6 (37.5%) and histochemistry in gastric adenocarcinoma. 2 (20%), respectively. 36 (52.9%) cases were Methodology: A total of 68 cases of gastric intestinal-type and 32 (47.1%) were signet ring adenocarcinoma were included and type and 3+ HER2/neu staining was 12 (33.3%), Immunohistochemical marker for HER2/neu was and 2 (6.3%), respectively. There were 3+ applied and evaluated on paraffin sections. positive in 14 (20.6%) cases, 0, 1+ negative in 38 HER2/neu overexpression according to age, (55.9%) cases and 2+ equivocal in 16 (23.5%). gender, site and histological type was determined. Conclusion: HER2/neu overexpression can be HER2/neu was assessed on the membrane determined in gastric adenocarcinoma by using staining of tumor cells. It was considered positive immunohistochemistry. Approximately 21% cases when more than 10% of the cells stained positively showed overexpression in our study. Larger in resection specimens and for biopsy specimens studies are required for more definitive results to at least 5 cells were positive. accurately determine proportion of patients who Results: Out of 68 cases, 42 (61.8%) were may benefit from trastuzumab therapy. (Rawal gastric cardia in origin , 1 6 ( 2 3 . 5 % ) o f Med J 202;45:537-540). gastoesophageal junction and 10 (14.7%) ofgastric fundus. 3+ HER2/neu staining in gastric cardia, gastroesophageal junction and gastric fundus was found to be 6 (14.3%), 6 (37.5%) and 2 (20%), respectively. 36 (52.9%) cases were intestinal type and 32 (47.1%) were signet ring type and 3+ HER2/neu staining was 12 (33.3%), and 2 (6.3%), respectively. There were 3+ positive in 14 (20.6%) cases, 0, 1+ negative in 38 (55.9%) cases and 2+ equivocal in 16 (23.5%).Conclusion: HER2/neu overexpression can be determined in gastric adenocarcinoma by using immunohistochemistry. Approximately 21% cases showed overexpression in our study. Larger studies are required for more definitive results to accurately determine proportion of patients who may benefit from trastuzumab therapy.
Publication Details
Page(s) 537-540
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 45, Issue: 3, Year: 2020

Request the full text from PASTIC

Keywords
HER2/neu, gastric fundus. 3+ HER2/neu staining in gastric Immunohistochemistry., Gastric adenocarcinoma
0

Citations

0

Downloads

104

Views